Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate

On February 20, Barclays initiated sum of Amgen Inc. (NASDAQ:AMGN) with an Equal Weight standing and a $185 terms target. The expert said determination is inactive “plenty of time” earlier the Phase 3 MARITIME proceedings results are released, which means the “biggest root of debate” astir Amgen volition stay unresolved for now. The steadfast besides noted it is “probably a spot much negatively inclined connected this than the Street,” though it said Amgen’s “strong” guidance helps equilibrium those concerns.

During Amgen’s Q4 2025 net call, Chairman and CEO Robert Bradway said the institution delivered coagulated show crossed its portfolio. He noted that 14 products generated much than $1 cardinal successful yearly sales, reaching blockbuster status. At the aforesaid time, 13 products posted double-digit growth, and 18 delivered grounds results. He said the spot and breadth of Amgen’s portfolio helped thrust double-digit maturation successful some gross and net per stock during 2025.

Bradway besides pointed to beardown maturation from cardinal products, including Repatha, EVENITY, and TEZSPIRE, each of which accrued much than 30% compared with the anterior year. He said these therapies are expected to stay large contributors to the company’s semipermanent growth. He added that Amgen’s uncommon illness concern generated much than $5 cardinal successful gross during the year. In oncology, maturation was supported by the company’s BiTE platform, with IMDELLTRA playing a cardinal role. Bradway said the attraction rapidly became the modular of attraction for patients with second-line oregon aboriginal tiny compartment lung cancer, driven by what helium described arsenic unprecedented endurance outcomes.

Amgen Inc. (NASDAQ:AMGN) is simply a biotechnology institution focused connected processing medicines for superior diseases. It works crossed areas with precocious unmet aesculapian needs and uses its probe and manufacturing capabilities to present caller attraction options.

While we admit the imaginable of AMGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 14 Best Real Estate Stocks to Buy According to Hedge Funds and 14 Best Warren Buffett Dividend Stocks to Buy

Disclosure: None.